Dr Irwin Wang, CEO of Reistone Biopharma, shares her motivations behind the establishment of the company, their extremely productive collaboration with Jiangsu Hengrui (China’s largest pharma company by market capitalization), and their exciting international clinical development strategy for their three assets.
I realized that if I wanted to establish a global biotech company in Shanghai, I should look to work with Chinese companies since they would be looking to work on global trials but would lack the necessary capabilities due to their lack of exposure to international markets
